Search

Your search keyword '"carmine musto"' showing total 2 results
Start Over Author "carmine musto" Journal jacc: cardiovascular interventions
2 results on '"carmine musto"'

1. Evaluation and Management of Nonculprit Lesions in STEMI

Author

Michael Maeng, Javier Escaned, Pieter C. Smits, Thomas Engstrøm, Niels van Royen, Matthias Götberg, Luís Raposo, Keith G. Oldroyd, Robin Nijveldt, Carmine Musto, Troels Thim, Nina W. van der Hoeven, Sérgio Bravo Baptista, and Anthony H. Gershlick

Subjects
medicine.medical_specialty, CFR, medicine.medical_treatment, Clinical Decision-Making, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Coronary Artery Disease, 030204 cardiovascular system & hematology, Revascularization, Severity of Illness Index, FFR, law.invention, STEMI, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, Randomized controlled trial, Recurrence, Risk Factors, law, Coronary Circulation, Internal medicine, medicine, Humans, In patient, 030212 general & internal medicine, Myocardial infarction, Nonculprit coronary lesions, business.industry, Coronary Stenosis, Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16], iFR, Recovery of Function, medicine.disease, Treatment Outcome, Cardiology, ST Elevation Myocardial Infarction, Cardiology and Cardiovascular Medicine, business, Coronary stenosis
Abstract

Contains fulltext : 220912.pdf (Publisher’s version ) (Closed access) Nonculprit lesions are frequently observed in patients with ST-segment elevation myocardial infarction. Results from recent randomized clinical trials suggest that complete revascularization after ST-segment elevation myocardial infarction improves outcomes. In this state-of-the-art paper, the authors review these trials and consider how best to determine which nonculprit lesions require revascularization and when this should be performed.

Published
2020

2. 3-Year Clinical Outcome of Patients With Chronic Total Occlusion Treated With Drug-Eluting Stents

Author

Antonio Parma, Marco Stefano Nazzaro, Giorgia Caferri, Carmine Musto, Francesco De Felice, Rosario Fiorilli, Roberto Violini, and Fernando Sbraga

Subjects
Bare-metal stent, Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Myocardial Infarction, Kaplan-Meier Estimate, bare-metal stent, Prosthesis Design, Risk Assessment, Disease-Free Survival, Coronary Restenosis, Coronary artery bypass surgery, Risk Factors, Internal medicine, medicine, drug-eluting stent, Humans, cardiovascular diseases, Angioplasty, Balloon, Coronary, chronic total occlusion, Aged, Proportional Hazards Models, Retrospective Studies, Chi-Square Distribution, business.industry, Patient Selection, Stent, Percutaneous coronary intervention, Drug-Eluting Stents, Thrombosis, Middle Aged, Surgery, Logistic Models, Treatment Outcome, Coronary Occlusion, Drug-eluting stent, Cardiovascular Diseases, Metals, Conventional PCI, Chronic Disease, Cardiology, Female, Stents, business, Cardiology and Cardiovascular Medicine, Mace, TIMI
Abstract

ObjectivesThe aim of this study was to evaluate whether percutaneous coronary intervention (PCI) with drug-eluting stent (DES) reduces major adverse cardiac events (MACE) in patients with chronic coronary total occlusions (CTO) compared with bare-metal stent (BMS) during 3-year follow-up.BackgroundThe long-term prognosis of patients with CTO treated with PCI and DES implantation is poorly investigated.MethodsWe compared the 3-year clinical outcome of 124 patients with CTO after successful PCI with DES implantation with that of 159 patients with CTO previously treated with BMS. MACE were defined as death, myocardial infarction, and target lesion revascularization (repeat PCI or coronary artery bypass surgery) and were considered as combined primary end point.ResultsAfter 3 years, the composite end point was significantly lower in the DES than in the BMS group: 18% versus 28%, respectively, (p < 0.05). The difference was due to the reduction of target lesion revascularization with DES compared with BMS—8% versus 21%, respectively, (p < 0.004). The Cox proportional hazards model identified: DES versus BMS (adjusted hazard ratio [HR]: 0.338, 95% confidence interval [CI]: 0.19 to 0.60, p = 0.0001), lesion length (HR: 1.033, 95% CI: 1.008 to 1.058, p = 0.012), and final minimal lumen diameter (HR: 0.456, 95% CI: 0.232 to 0.898, p = 0.023) as independent predictors of MACE at 3-year follow-up.ConclusionsAfter 3 years, DES were superior to BMS in reducing MACE in patients with CTO and should be considered the preferred treatment strategy.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results